PURPOSEGEMPAX was an open-label, randomized phase III clinical trial designed to assess the efficacy and tolerability of gemcitabine plus paclitaxel versus gemcitabine alone as second-line treatment ...

Pancreatic cancer is a disease in which malignant cells originate in the pancreatic tissue. Cancer of the exocrine component of the pancreas (adenocarcinomas) represents the majority of pancreatic ...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) in pancreatic cancer patients with a certain mutation.